Contrast enhanced ultrasound with Lumason for Kidney Cancer

Indiana University Hospital, Indianapolis, IN
Contrast enhanced ultrasound with LumasonPhase 4RecruitingLed by Jordan Swennson, MDResearch Sponsored by Indiana University

Study Summary

This trial will help doctors better understand how to use imaging to grade renal cell carcinoma, which in turn will help them make treatment decisions.

Eligible Conditions
  • Kidney Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You are scheduled to have a surgery to remove part or all of your kidney.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and first 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Correlation of contrast enhanced ultrasound features of renal masses with pathologic grade

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Renal malignancyExperimental Treatment1 Intervention
Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason

Find a site

Who is running the clinical trial?

Indiana UniversityLead Sponsor
938 Previous Clinical Trials
767,401 Total Patients Enrolled
Jordan Swennson, MDPrincipal Investigator
Indiana University

Media Library

Contrast enhanced ultrasound with Lumason Clinical Trial Eligibility Overview. Trial Name: NCT03821376 — Phase 4
Kidney Cancer Research Study Groups: Renal malignancy
Kidney Cancer Clinical Trial 2023: Contrast enhanced ultrasound with Lumason Highlights & Side Effects. Trial Name: NCT03821376 — Phase 4
Contrast enhanced ultrasound with Lumason 2023 Treatment Timeline for Medical Study. Trial Name: NCT03821376 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks have been associated with Contrast enhanced ultrasound using Lumason?

"A score of 3 reflects the fact that Contrast Enhanced Ultrasound with Lumason has been approved and is in Phase 4. Therefore, it can be assumed to have a high level of safety."

Answered by AI

Is there an ongoing call for participants in this experiment?

"Absolutely, according to this medical trial is actively searching for volunteers and was first posted on July 16th 2019. The most recent update was recorded as of 12th July 2022, with the aim of finding 40 individuals at a single site."

Answered by AI

Is this an original investigation?

"Utilizing Lumason with contrast enhanced ultrasound has been explored by researchers since 2017, when the first study to examine this intervention was sponsored by Bracco Diagnostics. Following a successful Phase < 1 drug approval in late 2017, 14 distinct medical studies have been launched across 10 urban centres located within 3 nations."

Answered by AI

What is the recruitment size of this experiment?

"Correct. The information hosted on corroborates that this research trial, which was originally posted to the platform in July of 2019, is actively searching for participants. 40 patients are required from a single location."

Answered by AI

Have there been precedents of Contrast enhanced ultrasound with Lumason in clinical trials?

"Currently, there are 14 active trials for Contrast enhanced ultrasound with Lumason, two of which currently reside in the third phase. Most take place at sites within Philadelphia, Pennsylvania; though overall there are 18 study locations across America."

Answered by AI
~11 spots leftby Jul 2025